Table 1.
Characters of patients concerning postoperative sorafenib therapy before and after PS match.
| Before match | After match | |||||
|---|---|---|---|---|---|---|
| Sorafenib (−) | Sorafenib (+) | p | Sorafenib (−) | Sorafenib (+) | p | |
| N = 312 | N = 154 | N = 131 | N = 131 | |||
| age | 50.7 + 11.6 | 53 + 11.9 | 0.048 | 52.7 + 10.9 | 52.4 + 12 | 0.825 |
| age ≥55 (%) | 121 (39) | 63 (40.9) | 0.762 | 55 (42) | 51 (38.9) | 0.706 |
| Male (%) | 269 (86.2) | 142 (92.2) | 0.067 | 113 (86.3) | 120 (91.6) | 0.237 |
| Max tumor size | 7.1 + 3.9 | 6.3 + 3.6 | 0.032 | 6.1 + 3.2 | 6.4 + 3.6 | 0.516 |
| size ≥5 cm (%) | 219 (70.4) | 94 (61) | 0.046 | 77 (58.8) | 82 (62.6) | 0.613 |
| Multiple tumors (%) | 56 (17.9) | 40 (26) | 0.051 | 33 (25.2) | 37 (28.2) | 0.675 |
| Vascular invasion (VI) | ||||||
| Macro-VI (%) | 32 (10.3) | 29 (18.8) | 0.008 | 13 (9.9) | 20 (15.3) | 0.267 |
| Micro-VI (%) | 114 (36.5) | 70 (45.5) | 0.098 | 50 (38.2) | 57 (43.5) | 0.451 |
| BCLC | ||||||
| 0/A | 243 (77.9) | 87 (56.5) | <0.01 | 84 (64.1) | 87 (66.4) | 0.404 |
| B | 37 (11.9) | 38 (24.7) | 27 (20.6) | 31 (23.7) | ||
| C | 32 (10.3) | 29 (18.8) | 20 (15.3) | 13 (9.9) | ||
| TNM Stage (I/II/III) | 163/89/60 | 54/45/55 | <0.01 | 60/35/36 | 49/40/42 | 0.386 |
| TB | 16.6 +23.8 | 17.6+ 10.5 | 0.612 | 16.4 + 14.7 | 16.2 + 7.9 | 0.889 |
| ALT | 48.6 + 38.6 | 60.9 + 89.4 | 0.038 | 49.6 + 40 | 53.9 + 63.2 | 0.520 |
| AST | 51.5 + 40.1 | 70.6 + 132.8 | 0.083 | 48.6 + 32.2 | 66.6 + 133.7 | 0.135 |
| ALB | 41.5 + 4.7 | 42.8 + 6.3 | 0.025 | 41.4 + 4.4 | 42.3 + 6.3 | 0.169 |
| Cirrhosis | 182 (58.7) | 94 (61) | 0.617 | 72 (55) | 76 (58) | 0.707 |
| Poor Differentiation (%) | 146 (46.8) | 61 (39.6) | 0.141 | 63 (48.1) | 54 (41.2) | 0.320 |
| HBV (%) | 283 (90.7) | 140 (90.9) | 0.597 | 115 (87.8) | 118 (90.1) | 0.694 |
| Child–Pugh grade A (%) | 305 (97.8) | 144 (93.5) | 0.033 | 128 (97.7) | 127 (96.9) | 1.000 |
| AFP ≥200 (%) | 147 (47.3) | 65 (42.2) | 0.548 | 56 (42.8) | 57 (43.5) | 0.801 |
BCLC, Barcelona Clinic Liver Cancer; TNM, tumor-node-metastasis; TB, total bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; ALB, albumin; HBV, hepatitis B virus; AFP, alpha fetoprotein.